Dosing in Obesity: A Simple Solution to a Big Problem
- 1 November 2007
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 82 (5) , 505-508
Abstract
The global epidemic of obesity has led to an increased prevalence of chronic diseases and need for pharmacological intervention. However, little is known about the influence of obesity on the drug exposure profile, resulting in few clear dosing guidelines for the obese. Here we present a semi-mechanistic model for lean body weight (LBW) that we believe is sufficiently robust to quantify the influence of body composition on drug clearance, and is therefore an ideal metric for adjusting chronic dosing in the obese.Keywords
This publication has 9 references indexed in Scilit:
- “Getting the Dose Right”: Facts, a Blueprint, and EncouragementsClinical Pharmacology & Therapeutics, 2007
- Quantification of Lean BodyweightClinical Pharmacokinetics, 2005
- Accuracy of Pharmacokinetic Models for Predicting Plasma Fentanyl Concentrations in Lean and Obese Surgical PatientsAnesthesiology, 2004
- What is the best size descriptor to use for pharmacokinetic studies in the obese?British Journal of Clinical Pharmacology, 2004
- Cyp2e1 Activity Before and After Weight Loss in Morbidly Obese Subjects With Nonalcoholic Fatty Liver DiseaseHepatology, 2003
- Caution when lean body weight is used as a size descriptor for obese subjectsClinical Pharmacology & Therapeutics, 2002
- Learning versus confirming in clinical drug development*Clinical Pharmacology & Therapeutics, 1997
- The Meaning and Measurement of Lean Body MassNutrition Reviews, 1991
- Clinical Pharmacy: Case StudiesDrug Intelligence & Clinical Pharmacy, 1974